REVIEW
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
Guy Ungerechts1,2, Sascha Bossow1, Barbara Leuchs4, Per S Holm5, Jean Rommelaere1, Matt Coffey6, Rob Coffin7, John Bell1 and Dirk M Nettelbeck8

Oncolytic viruses (OVs) are unique anticancer agents based on their pleotropic modes of action, which include, besides viral tumor cell lysis, activation of antitumor immunity. A panel of diverse viruses, often genetically engineered, has advanced to clinical investigation, including phase 3 studies. This diversity of virotherapeutics not only offers interesting opportunities for the implementation of different therapeutic regimens but also poses challenges for clinical translation. Thus, manufacturing processes and regulatory approval paths need to be established for each OV individually. This review provides an overview of clinical-grade manufacturing procedures for OVs using six virus families as examples, and key challenges are discussed individually. For example, different virus features with respect to particle size, presence/absence of an envelope, and host species imply specific requirements for measures to ensure sterility, for handling, and for determination of appropriate animal models for toxicity testing, respectively. On the other hand, optimization of serum-free culture conditions, increasing virus yields, development of scalable purification strategies, and formulations guaranteeing long-term stability are challenges common to several if not all OVs. In light of the recent marketing approval of the first OV in the Western world, strategies for further upscaling OV manufacturing and optimizing product characterization will receive increasing attention.

Molecular Therapy — Methods & Clinical Development (2016) 3, 16018; doi:10.1038/mtm.2016.18; published online 6 April 2016

INTRODUCTION
With recent marketing approval in the United States and recommendation for marketing approval in Europe of the first oncolytic virus (OV) in the Western world, T-Vec (brand name Imlygic),1,2 this new class of cancer drugs is now complementing surgery, chemotherapy, irradiation, targeted small molecules, and antibodies in routine clinical oncology. OVs implement a unique mode of action, tumor-restricted viral infection, replication, cell lysis, and spread.3,4 Notably, recent preclinical and clinical research has revealed pleiotropic therapeutic activity of OVs (Figure 1): (i) viral tumor cell lysis has been shown to trigger systemic antitumor immunity in animal models and patients;3,5–8 (ii) the insertion of therapeutic genes can trigger bystander killing by different means, depending on the chosen gene9, and (iii) endothelial cells specifically in tumor vessels were shown to be susceptible to OVs, resulting in vascular shut down and indirect destruction of tumor cells.10 As multitasking agents, OVs offer promising opportunities for treatment of heterogeneous tumors, avoidance of resistance development, and implementation of combination therapies. Research and clinical translation has recently focused especially on the vaccination effect and on the combination with (other) immunotherapies, foremost immune checkpoint inhibition.6–8 The fact that besides herpesvirus T-Vec OVs derived from several classes of viruses are being developed highlights the future potential of viral oncolysis1,11 (Figure 1). They represent a panel of pharmacophores that differ considerably with respect to their structure, size, genome, replication mechanisms, and host interactions including triggered host immune responses (Table 1). This diversity is further extended by the opportunity to genetically engineer OVs by a panel of different strategies (Table 1) aiming at better biodistribution and tumor specificity or at extending therapeutic applications, for example, by transgene expression as mentioned above. Moreover, by iterative translation cycles in a bench-to-bed-and-back approach, virus engineering facilitates overcoming emerging roadblocks to therapeutic efficacy. Notably, viruses from nine virus families are already in clinical investigation, and for some of these viruses, derivatives with different genetic modifications are being studied.3,11 The diversity of OVs clearly establishes promising therapeutic opportunities. The following are three examples: oncolytic measles

1Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; 2Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany; 3Department of Medical Oncology, National Center for Tumor Diseases and University Hospital, Heidelberg, Germany; 4Department of Tumor Virology, Infection, Inflammation and Cancer program, German Cancer Research Center (DKFZ), Heidelberg, Germany; 5Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; 6Oncolytics Biotech Inc., Calgary, Alberta, Canada; 7Replimune Ltd, Oxford, UK; 8German Cancer Research Center (DKFZ), Heidelberg, Germany. Correspondence: DM Nettelbeck (d.nettelbeck@dkfz.de) or G Ungerechts (gungerechts@ohri.ca)

Received 21 October 2015; accepted 12 January 2016
viruses located to tumor lesions and triggered durable complete remission after single systemic application in a patient with disseminated myeloma; T-Vec demonstrated immune-mediated systemic antitumor activity for metastatic melanoma patients after repeated intratumoral injections; and oncolytic vaccinia viruses showed the above-mentioned antivascular effect in patients with solid tumors. However, virus diversity also poses challenges for translation of viral oncolysis into clinical application: safety and manufacturing issues need to be addressed for each virus individually, because their relevant properties, such as genetic stability, biodistribution, and immunogenicity, might differ considerably.

This review provides a concise overview of clinical-grade manufacturing of six classes of OVs that are currently in clinical development: aden-, herpes-, measles, parvo-, reo-, and vaccinia viruses. Key facts and numbers for these viruses and their manufacturing are provided in Tables 1 and 2. As a condensed overview, five additional, essential aspects during the translation process of OVs into the clinics are presented in Figure 2. Major issues, challenges, and opportunities for virus manufacturing are discussed for each virus individually followed by a synopsis.

**ADENOVIRUSES**

Adenoviruses (Ads) are attractive oncolytic agents, based on their potent lytic activity, detailed knowledge of their structure and replication cycle, ample opportunities for virus engineering, and the high stability of virus particles and their genome. Different oncolytic Ads have been investigated in clinical studies, and the Ad Oncorine (H101) obtained marketing approval in China in 2005 (ref. 13). As with any new therapies, the translation of oncolytic (adeno-) viruses from the laboratory bench to their use in the clinic is subject to specific regulations and must meet several well-defined criteria for selectivity, potency, stability, identity, and product characterization (Table 2). Particular attention should be directed toward a detailed characterization of a stable good manufacturing practice (GMP) process, including the establishment of a master cell bank and a master seed virus and the development of sophisticated release assays. Thus, it is advisable that developers of oncolytic Ads contact local regulatory authorities at an early time point to discuss these issues.

For the production of oncolytic Ads, many producer cells, such as HEK293, are available and produce high Ad titer. However, since these cells possess genomic insertions of adenoviral E1 genes and
| Properties of selected oncolytic viruses covered in this review |
|---------------------------------------------------------------|
| **Herpesvirus: T-Vec (Imlygic)**                              |
| **Vaccinia virus**                                            |
| **Reovirus: REDYLSIN (pelareorep)**                           |
| **Adenovirus**                                               |
| **Measles virus**                                            |
| **Parovirus: H-1**                                           |
| **Genome**                                                   | dsDNA | dsDNA | dsRNA | dsDNA | Nonsegmented negative-strand RNA | Linear ssDNA |
| **Capsid**                                                   | Icosahedral | Brick shaped | Doublecapsid | Icosahedral | Helical nucleocapsid | Icosahedral |
| **Envelope**                                                 | Yes | No | No | No | Yes | No |
| **Genome/particle size**                                     | ~152 kbp/155–240 nm | 190 Kb/360×270×250 nm | 23,560 bp/85 nm | ~36 kbp/~90 nm | 15,894 nt (unmodified)/100–300 nm | 5,176 nt/~26 nm |
| **Host species**                                             | Human | Unknown | Pan mammalian | Human | Human | Rat |
| **Reported virus modifications for applications as oncolytics**| T-Vec: Deletion of ICP34.5 gene, Deletion of ICP47 gene, Insertion of transgene (encoding GM-CSF) | Pexa-Vec: Deletion of thymidine kinase gene, Natural mutation of B18R gene, Inclusion of human GM-CSF cDNA, Beta galactosidase gene | Eleven amino acid substitutions from the parental strain (primarily located in the L1 segment – RNA polymerase) | JX-929: Deletion of thymidine kinase gene and VGF gene | - | - |
| **Specific features**                                        | Insertion of GM-CSF gene | Multiple isoforms facilitate cell to cell spread and immune evasion, Stable in human serum, Excellent human safety record as multiple vaccine strains, Large capacity for encoding transgenes (50 Kb), Demonstrated ability to be delivered as an intravenous agent even in previously immunized patients, Antitumor vascular activity | Growth advantage in human cells | Particle and genomic stability, No integration into host genome, Low pathogenicity, High capacity for insertion of transgenes, High-titer production, Excellent knowledge of structure, genome, and replication cycle allows for modification, >50 serotypes infecting humans | - | - |
| **Reported virus modifications for applications as oncolytics**| Others: Deletion of further viral genes, Envelope modifications for specific oncotropism (entry “re-targeting”), Insertion of cellular promoters for tumor-targeted replication | - | Insertion of transgenes for therapeutic potentiation, biomonitoring, immunomodulation, Envelope modifications for specific oncotropism (entry “re-targeting”), Insertion of miRNA target sequences for increased safety, Insertion of aptamers for inducible replication | - | - | Insertion of transgenes for improved safety; Production of second-generation viruses through engineering/selection (preclinical) | - |
| **Specific features**                                        | - | - | Insertion of miRNA target sequences for increased safety, Insertion of aptamers for inducible replication | - | - | - |
| **Reported virus modifications for applications as oncolytics**| - | - | - | - | - | - |
| **Specific features**                                        | - | - | - | - | - | - |
Manufacturing clinical-grade oncolytic viruses

G Ungerechts et al.

Molecular Therapy — Methods & Clinical Development (2016) 16018 Official journal of the American Society of Gene & Cell Therapy

Clinical studies (numbers and phases, MTD, therapeutic activity)

| Herpesvirus: T-Vec (Imlygic) | Vaccinia virus | Reovirus: REOLYSIN (pelareorep) | Adenovirus | Measles virus | Parvovirus: H-1 |
|-----------------------------|---------------|--------------------------------|------------|--------------|----------------|
| **T-Vec**                  |               |                                |            |              |                |
| Phase 1 all comers (completed) |               |                                |            |              |                |
| Phase 1/2, pancreatic cancer (completed), i.t., NCT00402025 |               |                                |            |              |                |
| Phase 3, melanoma (completed), i.t., NCT00769704 |               |                                |            |              |                |
| Phase 2, melanoma (ongoing, to evaluate correlation between intratumoral CD8+ cell density and objective response rate), i.t., NCT02366195 |               |                                |            |              |                |
| Phase 1b/2, combination with ipilimumab in melanoma (ongoing), NCT01740297 |               |                                |            |              |                |
| Phase 1b/3, combination with pembrolizumab in melanoma (underway), NCT02653508 |               |                                |            |              |                |
| Phase 3, combination with cisplatin and radiotherapy in HNSCC (terminated), NCT0161498 |               |                                |            |              |                |
| **Pexa-Vec**               |               |                                |            |              |                |
| Multiple completed or ongoing phase 1 to phase 2b trials. Routes - intratumoral\(^4\); |               |                                |            |              |                |
| • Phase 1, various solid tumors (completed), NCT01169584 |               |                                |            |              |                |
| • Phase 1, HCC (completed), NCT00629759 |               |                                |            |              |                |
| • Phase 1/2, melanoma (completed), NCT00429312 |               |                                |            |              |                |
| • Phase 2a, HCC (completed), NCT00554372 |               |                                |            |              |                |
| i.v.\(^5\); |               |                                |            |              |                |
| • Phase 1, various solid tumors (completed), NCT00625456 |               |                                |            |              |                |
| i.v. followed by repeat i.t., i.v. dosing: |               |                                |            |              |                |
| • Phase 2b, HCC (completed), NCT01387555 |               |                                |            |              |                |
| • Phase 1b, CRC (ongoing), NCT01386060 |               |                                |            |              |                |
| Well-tolerated, flu-like symptoms. Demonstration of tumor site replication following i.v., antitumor vascular activity,\(^10\) antitumor immune response.\(^30\) |               |                                |            |              |                |
| Tumor response in multiple cancer types. Survival benefit following i.t. treatment in small phase 2 study (front line HCC),\(^42\) NCT00554372. |               |                                |            |              |                |
| Combination studies\(^51\): |               |                                |            |              |                |
| • Phase 1, combination with irinotecan in CRC (ongoing), NCT01394939 |               |                                |            |              |                |
| • Phase 2, combination with sorafenib in CRC (ongoing), NCT01171651 |               |                                |            |              |                |
| JJX-929: |               |                                |            |              |                |
| • Phase 1, various solid tumors, i.v., NCT00574977 |               |                                |            |              |                |
| Well-tolerated, flu-like symptoms. |               |                                |            |              |                |
| **Reolysin**               |               |                                |            |              |                |
| Twenty-one completed or ongoing single arm or randomized studies in the phase 1 or phase 2 setting. Single-agent objective responses have been demonstrated following i.t. or i.v. administration.\(^40\);\(^49\) Rate of response as monotherapy is modest, e.g. |               |                                |            |              |                |
| • Phase 2, stage iv. melanoma, (completed), NCT00651517 |               |                                |            |              |                |
| Higher response rates were observed when combined with pretreatments like ionizing radiation and chemotherapy, e.g. |               |                                |            |              |                |
| • Phase 2, combination with paclitaxel and carboplatin in HNSCC, (completed), NCT01166542 |               |                                |            |              |                |
| • Phase 2, combination with paclitaxel and carboplatin in NSCLC with KRAS or EGFR activation, NCT00861627; 1 and 2 year OS were 57% and 30% respectively. |               |                                |            |              |                |
| Combination studies\(^51\): |               |                                |            |              |                |
| • Phase 2, combination with gemcitabine in advanced pancreatic adenocarcinoma (completed), NCT00998322 |               |                                |            |              |                |
| Evidence of viral replication in tumor following systemic delivery.\(^52\) |               |                                |            |              |                |
| **DNX-2401**               |               |                                |            |              |                |
| • Phase 1, glioma, i.t., NCT02197169 |               |                                |            |              |                |
| • Phase 1/2, glioma, i.t., NCT01582516, NCT01956734 |               |                                |            |              |                |
| **CG0070**                 |               |                                |            |              |                |
| • Phase 2, bladder, intravesical, NCT02365818 |               |                                |            |              |                |
| **ICOVIR-SP**              |               |                                |            |              |                |
| • Phase 1, melanoma, endovenous, NCT01864759 |               |                                |            |              |                |
| • Phase 2, solid tumors, i.v., NCT01844661 |               |                                |            |              |                |
| **VCTN-01**                |               |                                |            |              |                |
| • Phase 1, solid tumors, i.t., NCT02045589, i.v., NCT02045602 |               |                                |            |              |                |
| **ONCOS-102**              |               |                                |            |              |                |
| • Phase 1, solid tumors (completed), i.t. and i.v., NCT01598129 |               |                                |            |              |                |
| **Golo-Ad1**               |               |                                |            |              |                |
| • Phase 1/2, solid tumors, i.t. or i.v., NCT02053220; i.v., NCT02024442; intraperitoneal injection, NCT02028117 |               |                                |            |              |                |
| **MV-CEA/MV-NIS**          |               |                                |            |              |                |
| • Phase 1, glioblastoma multiforme (clinical assessment in progress), i.t., NCT00390299 |               |                                |            |              |                |
| **MV-CEA**                 |               |                                |            |              |                |
| • Phase 1, glioblastoma (completed), i.t. or i.v., NCT01301430 |               |                                |            |              |                |
| **MV-NIS**                 |               |                                |            |              |                |
| • Phase 1, pleural mesothelioma, intrapleural injection, NCT01503177 |               |                                |            |              |                |
| • Phase 1, HNSCC (ongoing), i.t., NCT01846091 |               |                                |            |              |                |
| • Phase 1/2, multiple myeloma (ongoing), i.v., NCT00450814 |               |                                |            |              |                |
| • Phase 2, multiple myeloma (ongoing), i.v., NCT02192775 |               |                                |            |              |                |
| • Phase 2, ovarian, fallopian or peritoneal cancer, i.p. injection, NCT02364713 |               |                                |            |              |                |
| **MV-CEA / MV-NIS**        |               |                                |            |              |                |
| • Phase 1, ovarian cancer (clinical assessment in progress), intraperitoneal injection, NCT00408590 |               |                                |            |              |                |
| **MV-NIS**                 |               |                                |            |              |                |
| • MTD not reached. Evidence of virus replication, cytotoxicity and immunostimulation in treated tumors. Virus crossing of the blood–brain barrier after i.v. administration. Clinical assessment in progress |               |                                |            |              |                |

References 53–55

50, 46, 47

10, 42, 43, 46, 47, 50, 51

48, 49, 52, 56–64

13, 65–68

12, 33, 68–70

71–73 and Leuchs B et al., manuscript submitted

CRC, colorectal cancer; GM-CSF, granulocyte-macrophage colony-stimulating factor; HCC, hepatocellular carcinoma; MTD, maximum tolerated dose.
oncolytic Ads contain E1 deletions or modifications, recombinations can occur reverting the modified E1 gene of oncolytic Ads to wild-type sequence. This problem can be encountered by the selection of a thoroughly characterized cell line that does not have integrated adenoviral sequences.\textsuperscript{18} An additional challenge is a consistent surveillance of master cell bank and master seed virus used in the production of oncolytic Ads that included tests for the cellular identity and the absence of any adventitious contaminants, such as mycoplasma and bovine/porcine viruses.\textsuperscript{14}

Different production methods for viral particle (vp) have been described in the literature,\textsuperscript{19–23} including the growth of producer cells in suspension using serum-free medium. However, the production of oncolytic Ads under serum-free conditions causes a significant reduction in virus yield. In addition, the production of oncolytic Ads is also affected by the so-called cell density effect that limits the production of Ads at cell densities of $< 1 \times 10^6$ cells/ml.

The most popular method for the purification of oncolytic Ads is the use of two rounds of cesium chloride density gradient ultracentrifugation. This method can provide sufficient material for phase 1 trials but has the disadvantage of not being scalable. Therefore, for large-scale manufacturing of clinical-grade oncolytic vectors exceeding $>10^{15}$ vp, column chromatographic methods, including anion exchange chromatography, have been developed.\textsuperscript{24–26} During virus production and purification steps, the upstream and downstream processing is time consuming and causes considerable production costs. Thus, it is important to establish a method, which enables the monitoring of virus titer in every single production step during upstream and downstream processing.

Purified viruses should be tested for potency, identity (endpoint PCR, restriction analysis, or sequencing), sterility, purity, endotoxin, contaminating host cell DNA ($\leq 5$ pg/10\textsuperscript{11} vp), and proteins (Table 2). Total vp and infectious particles (ip) are two critical parameters for comparison of different production processes and should be determined carefully.\textsuperscript{14} The Food and Drug Administration recommends a vp/ip ratio of 30. A high deviation from this value should be avoided (although a certain ratio is not specified by the European regulatory agency).

It is of decisive importance to choose an appropriate immunocompetent animal model for testing toxicity and biodistribution studies of oncolytic Ad. In this regard, it has been shown that Syrian hamster support viral replication in several organs.\textsuperscript{17} Such studies might be performed with “lab-derived material” if the comparability of the “lab material” and the GMP material has been shown unequivocally.

**HERPESVIRUSES**

Herpes simplex virus (HSV) is a large, enveloped, double-stranded DNA virus, which between the envelope and capsid contains a region known as the tegument, containing over 20 HSV proteins, which is essential for infectivity. The envelope carries 12 glycoproteins, and the capsid is composed of 7 different proteins. As such, manufacturing of HSV presents a number of challenges. These include the large size of the virus (155–240 nm), including that it is enveloped, which needs to be kept intact throughout the purification process. As HSV is complex, full characterization of the final product can also be challenging. The 152 Kb genome has both long and short unique regions each flanked by terminal repeat regions which are present in the four possible orientations in relation to each other. The repeated regions mean that some HSV genes (e.g., ICP34.5—see later) are present twice in the genome, and the different orientations mean that an HSV stock contains capsids containing each of these isomers.\textsuperscript{28} Both of these properties of the HSV genome can also complicate characterization.

Oncolytic versions of HSV have one or more nonessential genes deleted, in some cases combined with the insertion of a therapeutic transgene.\textsuperscript{8} A nonessential gene is unnecessary for replication in vitro but is required for pathogenicity in vivo. Those deleted or mutated genes in candidate oncolytic viruses include ICP34.5 (the neurovirulence factor that provides the greatest attenuation of pathogenicity in vivo while still allowing replication in vivo), thymidine kinase (not only necessary for sensitivity to acyclovir and similar drugs but also required for efficient replication in vivo), ICP6 (the large subunit of ribonucleotide reductase), and ICP47 (which blocks antigen presentation by transporter associated with antigen processing). Insertions include a number of cytokines, including IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Talimogene laherparepvec (T-Vec, brand name Imlugic, Amgen, Thousand Oaks, CA) is the most advanced in clinical development and is deleted for ICP34.5 and ICP47 containing an insertion of the gene encoding GM-CSF under CMV promoter control in place of ICP34.5 (ref. 29).

From a purification perspective, standard procedures used for the production of live attenuated viral vaccines are generally employed, including harvest of the supernatant from infected producer cells, size exclusion chromatography, ion-exchange chromatography, Benzonase treatment to remove contaminating DNA, sterile filtration, and filling of final product. To avoid centrifugation, use of tangential flow filtration can be employed for concentration and/or buffer exchange between steps, but if so care needs to be taken regarding the shear forces exerted so as not to disrupt the complex virion, as is also the case for terminal sterile filtration if employed. Careful optimization of each of these steps is required. For characterization, western blotting to confirm the presence and relative abundance of key viral proteins can be used and product-specific PCR or Southern blot to confirm genome structure (Table 2). Potency assays will not only depend on the nature of any transgene but also seek to confirm oncolytic activity in appropriate cells. While these processes and procedures are generally robust, future improvements may seek to increase yields at each step and long-term stability at ambient or refrigerated temperatures.

**MEASLES VIRUSES**

Oncolytic measles viruses (MV) based on attenuated vaccine strains are currently under investigation in clinical trials (Table 1) as a promising modality of cancer treatment with the potential to induce immune-mediated tumor rejection. MV vaccine strains are oncolytic by preferentially entering tumor cells through CD46 (ref. 30), a membrane protein that is typically overexpressed in malignant cells.\textsuperscript{31}

In contrast to using MV as a vaccine, oncolytic activity as an advanced therapy medicinal product depends on high concentration of infectious particles. While the size range of pleomorphic MV particles is often quoted as 100–300 nm,\textsuperscript{12} in practice, MV must be treated as $>1$ µm particles that are extremely shear sensitive, to maximize recoveries and retain infectivity. Therefore, the entire production and purification process has to be done under gentle and aseptic GMP conditions.\textsuperscript{12} Clinical batches of MV are produced in Vero cells adapted to serum-free growth in cell factory multilayer vessels, resulting in 50% of the virus in the supernatant and 50% staying associated with the cells. The supernatant is clarified by filtration and treated with Benzonase to digest contaminating nucleic acids. MV particles are then concentrated and purified using
Table 2: Overview of production, purification, and characterization of clinical grade oncolytic viruses

| Producer cell(s) (name, species, tissue, genetic modifications if applicable) | Herpesvirus: T-Vec (Imlygic) | Vaccinia virus | Reovirus: REOLYSIN (pelareorep) | Adenovirus | Measles virus | Parvovirus: H-1 |
|---|---|---|---|---|---|---|
| Vero (african green monkey, kidney) | HeLa cells (human cervical carcinoma, HPV sequences) | HEK293, suspension (human, kidney, inserted adenoviral sequences) | Vero cells (african green monkey, kidney), adherent | Vero cells (african green monkey, kidney), adherent | Human newborn kidney cells (SV40 transformed nonproducer cells), adherent |
| BHK (hamster, kidney) | | | | |
| H-1 | | | | |

| Culture vessels | Flasks, roller bottles, cell factories or bioreactors | Adherent culture vessels, cell factories, RC-40 roller bottle packs | 100 l stir tank reactor | Spinner, roller bottle, bioreactor, single-use bags | Cell factory | Cell factory |
|---|---|---|---|---|---|---|
| Culture media; volume for final amplification step; cell density, or total number of cells | DMEM; up to 100 l | DMEM containing 10% fetal bovine serum, pH 7.3, for 40 extended surface roller bottles (34,000 cm²). Approximately 4E05 cells/cm² and 1 l of DMEM per bottle | Custom media optimized for HEK293 growth and viral production; 100 l | VP-SFM (serum-free, Invitrogen), glutamine; 25–50 l ~1E05 cells/cm²; ~2E10 total | | |
| Virus purification method | Centrifugation, size exclusion and ion exchange chromatography, membrane chromatography and filtration | Whole cell harvest followed by hypo-osmotic shock, clarification of cell lysate by depth filtration, DNase (Benzonase) and protease treatment (TrypLE), tangential flow filtration and diafiltration. | Clarification of feed stock followed by UF/DF; final steps are anion exchange chromatography followed by size exclusion chromatography; terminal 0.22-µm filtration | a) CsCl-density gradient ultracentrifugation b) HPLC | Physical virus release from cells; clarification (filtration 3 µm); DNase treatment (Benzonase); tangential flow filtration and diafiltration; polishing (filtration 1.2 µm) | Physical virus release from cells; clarification (filtration); density gradient centrifugation |
| Storage buffer formulation | PBS plus sugars | TrisBuffer plus sugars | Modified PBS | 5% glycerol, 25 mmol/l NaCl, 20 mmol/lTris | 5% sucrose, 50 mmol/l Tris–HCl (pH 7.4), 2 mmol/l MgCl₂ | Visipaque/Ringer solution (approved for human use) |
| Recovery (vp or ip per total volume or per cell) | Confidential | ip: 5E12 (from 40 l) | vp: 4.31E16; ip: 2.45E15 TCID<sub>50</sub> (from 100 l) | vp: 1E15; ip: 5E13 TCID<sub>50</sub> (from 100 l) | | 1E05 vp/cell; 1E03 ip/cell |
| Max. virus concentration (ip/ml) | 1E09 | 1E09 | 3.62E11 TCID<sub>50</sub> (from 100 l) | 4E10 to 5E11 TCID<sub>50</sub> (from 30 l) | 4E09 | 1E11 |
| Typical ratio vp/ip | 10–50 | 50–100 | 15 | 10–50 | 50–100 | 100–1,000 |
| Method to determine vp; ip: plaque assay or TCID<sub>50</sub> assay | ip: plaque assay; vp: qPCR | vp: HPLC; ip: TCID<sub>50</sub> assay | vp: OD 260 nm, real-time PCR; ip: plaque assay, end-point dilution assay, electron microscopy | vp: qRT-PCR (N gene copies per ml); ip: TCID<sub>50</sub> assay | vp: qPCR (full particles), capsid-ELISA (full + empty particles); ip: plaque assay |

Table 2: Continued on next page
### Table 2  Continued

| Virus Species | Herpesvirus: T-Vec (Imlygic) | Vaccinia virus | Reovirus: REOLYSIN (pelareorep) | Adenovirus | Measles virus | Parvovirus: H-1 |
|---------------|-----------------------------|---------------|-------------------------------|------------|--------------|----------------|
| **Application route** | i.t.: 1E06 to 1E08<sup>53</sup> (ref. 43) | i.t.: 1E08 to 1E09<sup>12</sup> (ref. 43) | i.v.: standard dose is 3E10 TCID<sub>50</sub> | i.t.: 3E10 to 3E12 vp<sup>74</sup> | i.t.: 1E09 ip<sup>69</sup> | i.t.: 1E06 to 5E09 ip<sup>17</sup> |
| **Molecular characterization of virus identity** | Virus species identity and presence of any inserted genes confirmed using antibody-based assays, Southern blot and/or PCR | Q-PCR for presence of transgenes, Q-PCR for confirmation of gene deletions, Western blotting and bioactivity assays for transgenes, Sanger sequencing if applicable | Identity by western blotting, Q-PCR and Sanger sequencing; End point PCR, restriction analysis, sequencing | Identity by western blotting, Q-PCR and Sanger sequencing; End point PCR, restriction analysis, sequencing | Identity: RNA by RT-PCR, sequencing; protein by western blot; transgene expression (if applicable) | Identity: DNA by sequencing, protein by western blot/virus particles by capsid ELISA, electron microscopy |
| **Purity, toxicity and release criteria** | Absence of process-related impurities (residual host cell protein, host cell DNA, critical ingredients e.g. residual DNase, residual CsCl (adenovirus)), adventitious agents (e.g., cell dissociation enzyme) | Absence of product-related impurities (e.g., vp/ip ratio, for adenovirus: replication-competent (wild-type) Ad testing) and sub-visible particles | Absence of contaminants: mycoplasma, sterility, bioburden, abnormal toxicity (virus unrelated) and extraneous agents (in vitro and in vivo) | Titer, identity (see above), pH, osmolality, appearance, potency, extractable volume | Titer, identity (see above), pH, osmolality, appearance, potency, extractable volume | Titer, identity (see above), pH, osmolality, appearance, potency, extractable volume |
| **Assays for analysis of efficiency of virus preparation** | Virus titration and potency of any inserted genes | Virus titration and potency/bioactivity of inserted transgenes | Virus titration | a) Potency assay at low MOI in different tumor cells versus normal cells, b) *In vivo* xenograft model | Virus titration; potency assay on test cells | Potency assay on target tumor cells |
| **Other procedures/features** | None | Stability at RT, 4 °C to −20 °C and −65 °C | None | None | In vivo: a) Biodistribution studies by PCR, b) Virus replication in lungs of Syrian hamster | Stability (≥ 6 years at ≤ −65 °C) | Stability (≥ 4 years at ≤ −60 °C) |

GMP, good manufacturing practice; ip, infectious particles; MOI, multiplicity of infection; vp, (physical) virus particles.

*According to USP or/and Ph.Eur. in compliance with e.g. US Food and Drug Administration, European Medicines Agency, GMP International Council of Harmonization.
tangential flow filtration and diafiltration, followed by a final passing through a clarifying filter prior to vialing and storage at $<-65\ ^\circ\text{C}$.

Previously, various compounds and excipient formulations have been tested as stabilizers to protect the integrity of the viral envelope (e.g., viral infectivity) and also to inhibit aggregation of vp. MV formulated with a buffered sucrose solution containing additionally magnesium chloride showed enhanced physical stability providing virus longevity of more than 6 years, with stable infectivity of the sensitive agent.

Current batch preparations meet the requirements for clinical trials, but purity may be further improved. MV products are tested for identity, purity, potency, adventitious agents, contaminating host cell DNA, and proteins (Table 2). The ratio between total vp and ip is a critical parameter for the quality of virus preparations. Although a certain vp/ip ratio is not specified by the regulatory agencies, a value of $\approx50$ in MV preparations can be assumed on average. Residual DNA from host cells in the final product is one of the concerns in the manufacturing process of MV as an advanced therapy medicinal product. For the commercially produced MV vaccine, the WHO recommends values $\leq100\ \text{pg per dose (i.e., 1,000 ip)}$. But for the use of high doses of MV in cancer therapies (e.g., $10^9\ \text{ip}$ for intratumoral injections), the limit for expectedly higher amounts of residual host DNA in the final product has to be coordinated with the regulating authorities.

Currently, several strategies are pursued to improve overall yield and purity of MV preparations. Cultivation using microcarriers or switching to suspension cells in bioreactors may lead to higher titers. Also, development of virus compatible, chromatographic procedures (ion exchangers) may be an option to contribute to the removal of non–particle-associated nucleic acids and proteins, thereby improving the quality of clinical MV batches.

PARVOVIRUSES H-1PV
Several aspects of the biology of rodent protoparvoviruses (PVs), in particular H-1PV, make these agents attractive for the development of anticancer strategies (see Table 1, specific features). Some of these properties also impact on the procedures used for clinical-grade virus production, purification, and quality/quantity control. First of all, the low natural infectivity of PVs and their lack of association with human diseases minimize the precautions to be taken to protect the staff involved in virus manipulation. Furthermore, the high stability (and concomitant longevity) of infectious virions (tolerance to heating, extreme pH, and desiccation) makes their handling significantly easier.34

Besides these general factors, specific steps in virus batch preparation rely on physicochemical or biological features of PVs. (i) The compact physical (and genetic) structure of the virions (parvus = small) allows filtration to be used in purification and sterilization processes. (ii) Mature PVs are stable in the presence of lipid solvents which can thus be applied to virus release and purification. (iii) Full and empty PVs have distinct densities and can be isolated and concentrated through gradient centrifugation. (iv) PVs are among the most resistant pathogens to inactivation by gamma irradiation. Advantages could be taken of this resistance to inactivate microbial contaminants in PV samples. (v) Human cells can be used for efficient PV production, thereby avoiding the risk of batch contamination with animal microbes and immunogenic animal proteins. (vi) Producer cells can be adapted to suspension culture, raising the possibility of PV production upscaling in bioreactors. (vii) Through the establishment of master virus banks, clinical batches are obtained after infection, avoiding the need for transfection reagent testing of final products. (viii) PV formulation with Visipaque/Ringer solution allows computer tomography visualization of the inoculum, precise local delivery, and absence of backflow due to higher viscosity. Virus longevity for more than 4 years was demonstrated in this formulation, with little aggregation and stable infectivity (Leuchs B, et al., unpublished data).

Current PV batch preparation meets the requirements for clinical trials but still calls for further improvements. Special efforts are currently done to select producer cells adapted for large-scale cultivation in serum-free and optimized medium, using microcarrier or suspension bioreactors (e.g., wave or stirring). Since density
centrifugation of large virus harvests is cumbersome, the development of chromatographic procedures with ion exchangers or membrane absorbers is needed to optimize and shorten PV purification steps. This should contribute to improve the removal of cellular and non–particle-associated viral DNA and proteins and to enhance the specific infectivity of PV clinical batches.

**REOVIRUSES: REOLYSIN (PELAREOREP), A UNIQUE ISOLATE OF REOVIRUS T3D (TYPE 3 DEARING)**

REOLYSIN, also known as pelareorep, is a proprietary isolate of the replication-competent reovirus type 3 Dearing, a non-enveloped double-stranded RNA virus that possesses an intrinsic preference to replicate and subsequently lyse tumor cells with Ras pathway activation.35 The selective lysis of cells with an activated Ras pathway by reovirus arises from the inhibition of the autophosphorylation of dsRNA-activated protein kinase (PKR), thereby disabling the cells’ protective antiviral mechanism. Several groups have demonstrated that reovirus-induced lysis of tumor cells stimulates a potent antitumor immune response which is composed of both innate immune activation and adaptive immune responses.36–38

For the production of oncolytic reovirus in clinical applications, the cell culture process consists of thawing vials of human embryo kidney (HEK293S) cells and seeding in T-flasks with a proprietary medium supplemented with glutamine. Cell expansion continues using T flasks and/or increasing sizes of Erlenmeyer flasks, with passages every 3 to 3 days until a sufficient number of cells is achieved to seed a WAVE bioreactor in which further expansion occurs. Subsequently, the stirred-tank bioreactor is seeded, and the cells are further expanded until an optimal number of cells are present for infection. After achieving the desired HEK293S cell count, the infection step, in which virus is added to the bioreactor containing the HEK293S cells, takes place. Virus is harvested using a Triton lysis step, then a Benzonase treatment for degradation of residual nucleic acids, followed by purification of the lysate. The downstream purification process begins with chilling of the lysate and clarification through an 8.0-µm filter, followed by 3.0/0.8-µm filtration. After overnight storage, the clarified lysate is ultrafiltered and diafiltered through a hollow fiber filter, followed again by overnight storage. Two chromatography steps—ion exchange and gel permeation—are completed prior to final 0.22-µm filtration. Recovery of infectious particles by this methodology averages 40%.

Identity testing of pelareorep as a reovirus T3D strain has been confirmed by western blotting and confirmed in detail through genomic sequencing and comparison to GenBank sequences. As part of routine analytical testing on each lot of pelareorep produced, the identity of pelareorep is confirmed to be reovirus T3D by QPCR. A more specific identity test to confirm pelareorep identity is Sanger sequencing, which has recently been validated for use in the routine identity testing of pelareorep. The new Sanger sequencing method identifies five unique modifications in the L1 genome segment of reovirus T3D and thereby is specific to REOLYSIN.39

Drug substance testing is assayed for appearance, mycoplasma, adventitious viral contamination, identification, potency (virus titer), content (virus particle concentration), bioburden, residual HC DNA, residual HCP, and residual Benzonase (Table 2).

The greatest historical challenge in the production of the virus was related to deficiencies in the commercially available animal-component free cell culture medium that was used in early process development. This medium was optimized for the production of HEK293 suspension cells rather than the production of virus. This medium was further limiting in that it did not support cell growth beyond 2E6 cells/ml, contained phenol red which interfered with the anion exchange step, and allowed for the accumulation of ammonia which prevented reovirus uncoating, which in turn limited virus production in the bioreactor. To address these shortcomings, Oncolytics (Oncolytics Biotech., Calgary, Alberta, Canada) worked with third-party manufacturing experts to create an optimized medium that was able to optimize cell growth as well as virus production, principally by limiting ammonia production in the bioreactor. This leaner media improved the quality of the feedstock and improved recovery more than fourfold as compared to the commercially available medium.

**VACCINIA VIRUSES**

The extensive human safety data that is available for vaccinia viruses as a consequence of their more than 200 hundred year use as a vaccine for small pox infections makes this a very attractive platform as an oncolytic therapeutic. In addition, the virus can harbor and express in excess of 50 Kb of therapeutic transgenes and has multiple known mechanisms of action against tumors in both rodents and humans.40 Vaccinia viruses were the first to demonstrate consistent and convincing infection of tumor beds following i.v. administration41 and in a small randomized trial demonstrated some signs of survival benefit in a subset of hepatocellular carcinoma patients.42

Despite these encouraging results, there still exist several challenges to the widespread commercialization of the vaccinia OV platform even when it achieves clinical success in phase 3 studies. Like other OV platforms, large doses of viral product, well in excess of vaccine doses, need to be administered to patients in order to see effective delivery to tumors following i.v. administration.43 To achieve these doses, virus is best produced in adherent tumor cell cultures in serum-containing medium. To satisfy regulatory concerns, extensive testing of viral product to ensure that no oncogenic DNA is found in the final product needs to be done.

In addition, vaccinia remains largely cell associated and requires cell disruption followed by enzyme digestion steps to liberate the virus from cell debris and reduce host cell contaminants. An additional challenge to the manufacture of pharmaceutical-grade vaccinia virus is that its relatively large size prevents passing through “sterilizing filters” commonly of 0.2 µm or smaller pore size. This means that the entire manufacturing process must be done aseptically. Like many virus products, vaccinia is extremely stable when stored at −80 °C, but additional formulation studies need to be performed to create a pharmaceutical-grade product that can be routinely stored at −20 °C, 4 °C, or perhaps even at room temperature.

Further process development studies still need to be undertaken to optimize the production of oncolytic vaccinia viruses. Ideally, a serum-free suspension cell platform for producing high-titer virus preparations would be preferred. If adherent cell cultures remain required for satisfactory yields, high-intensity bioreactors like the macrofibre iCellss system or manufacturing cells grown on microcarriers should be explored.

Currently, downstream purification of vaccinia virus products has been limited to tangential flow filtration strategies, but the similar size of vaccinia to apoptotic bodies released from dying cells limits the ability to purify the virus from contaminating host protein and nucleic acids. An orthogonal purification strategy independent of particle size is preferred. Vaccinia virus has multiple isoforms, and one version called extra enveloped virus is thought to have the advantage of evading neutralizing antibodies.44 Current manufacturing processes focus on harvesting cell-associated viruses that would not include extra enveloped virus isoforms. Strategies that
enrich and stabilize the somewhat delicate extra enveloped virus form of the virus could create products that could be more effectively delivered to immunized patients.

SYNOPSIS AND FUTURE PERSPECTIVES

Robust and readily scalable manufacturing processes have been developed to produce various oncolytic viruses suitable as a drug for clinical studies. Starting from an established, GMP-certified master cell bank and a characterized master seed virus, the crude product could be more effective and stabilized to some extent during the infection process for licensed product manufacturing, it could be necessary to investigate bioreactor technology using adherent cells on microbeads or suspension cell cultures to support the production of OVAs at desired higher titers. Ideally, cell growth would occur in serum-free medium to completely eliminate animal-derived components during GMP. Disposable single-use stirred tank bioreactors with high volumes would be suitable for virus manufacturing purposes. Downstream purification processes, especially separation from subcellular structures, may need optimization in some cases, depending on the size and density of the virus particle. Quality control is the part of GMP that is concerned with sampling, specifications, testing, documentation and release procedures. It ensures that the necessary and relevant tests are carried out and that all required materials are released for use only if their quality is satisfactory.

Before using a virus lot in clinical trials, it is necessary to submit an investigational new drug application to the regulatory authorities that contains all the information regarding production and testing of the clinical-grade OV, including its preclinical efficacy, biodistribution, and pharmacological/toxicological testing in laboratory animals, and the draft clinical protocol. It is highly recommended to keep the regulatory authorities informed regarding any difficulties encountered during lot release testing and to seek their input and guidance at all key steps in the clinical reagent development process. It may seem on the surface that replication-competent viruses as oncolytic agents could be uniformly evaluated in terms of manufacturing and approval for clinical studies. But release criteria basing on validated test methods to characterize identity, purity, potency, and safety of the OV products (Table 2) can vary taking the nature of the respective virus type into account due to its inherent, biologically specific properties like size, host species, tropism, etc. Thus, to find common ground, most release criteria of clinical OV platforms were derived from those defined in GMP specifications of viral vaccine drugs, most of them consisting of formulations with low amounts of vp sufficient for establishing the desired vaccination effect. However, current OV platforms require large doses of viral product, well in excess of vaccine doses, in order to see effective delivery to tumor sites and therapeutic effects. Higher virus concentrations often come along with accumulation of impurities like residual cellular host DNA. Eliminating this by more extensive purification procedures, virus particles may suffer resulting in a higher ratio of vp:ip, often depending on the nature of the virus type.

Deviations in the release criteria of the final product have to be coordinated with the local regulating authorities responsible for the site where the clinical study is planned to be conducted. As the authorities often define country-specific acceptance criteria, this might pose a problem for clinical trials intended as multicenter studies, especially when recruiting a large pool of patients in several continents for phase 3 trials. Therefore, a global harmonization of approval criteria and processes between the local regulatory authorities (e.g., Food and Drug Administration, Health Canada, European Medicines Agency, and International Council of Harmonization) could be a helpful development for future attempts to bring oncolytic virus platforms into the clinic at a faster and higher extent.

CONFLICT OF INTEREST

Matt Coffey is employee of Oncolytics Biotech Inc., Calgary, Alberta, Canada. Rob Coffin is employee of Replimune Ltd, Oxford, UK.

ACKNOWLEDGMENTS

We thank Mark Federspiel for proofreading the MV manufacturing part. The H-1PV process development and the pre-clinical and clinical trial is supported by Oryx GmbH & Co. KG, Germany.

REFERENCES

1. (2015). First oncolytic viral therapy for melanoma. Cancer Discov 6:5.
2. Sheridan, C (2015). First oncolytic viral therapy for melanoma. Cancer Discov 6:5.
3. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30:658–670.
4. Bell, J and McFadden, G (2014). Viruses for tumor therapy. Cell Host Microbe 15:260–265.
5. Kaufman, HL, Kim, DW, DeRafelle, G, Mitchell, J, Coffer, RS and Kim-Schulze, S (2010). Local and distant immunity induced by intratrabecular vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17:718–730.
6. Lichty, BD, Breitbach, CJ, Stojdl, DF and Bell, JC (2014). Going viral with cancer immunotherapy. Nat Rev Cancer 14:559–567.
7. Woller, N, Guileviuk, I, Ureche, Cl, Schumacher, A and Kühnel, F (2014). Oncolytic viruses as anticancer vaccines. Front Oncol 4:188.
8. Coffer, RS (2015). From virotherapy to oncolytic immunotherapy: where are we now? Curr Opin Viral 13:93–100.
9. B azou, M and Hermiston, T (2014). Armed therapeutic viruses – a disruptive therapy on the horizon of cancer immunotherapy. Front Immunol 5:74.
10. Breitbach, CJ, Arulanandam, R, De Silva, N, Thorne, SH, Patt, R, Daneshmand, M et al. (2013). Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 73:1265–1275.
11. Miest, TS and Cattaneo, R (2014). New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 12:23–34.
12. Russell, SJ, Federspiel, MJ, Peng, KW, Tong, C, Dingli, D, Morice, WG et al. (2014). Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 89:926–933.
13. Larson, C, Cronsky, B, Scicinski, J, Fanger, GR, Stem, M, Oronsky, A et al. (2015). Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 6:19976–19989.
14. Wisher, M (2002). Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther 9:1056–1061.
15. Nadeau, I and Kamen, A (2003). Production of adenovirus vector for gene therapy. Biotechnol Adv 20:475–489.
19. Kamen, A and Henry, O (2004). Development and optimization of an adenovirus production process. *J. Gene Med* 6 (suppl. 1): S184–S192.

20. Lesch, MP; Heikkilä, KM; Lipponen, EM; Valonen, P; Muller, A; Räisänen, E et al. (2015). Processes of yield improvement for the benchmark to commercial scale. *Hum Gene Ther* 26: 560–571.

21. Challengers in mastering adenoviral vectors for global vaccine product deployment. *Hum Gene Ther* 25: 318–327.

22. Vellinga, J, Smith, JP, Lipiec, A, Majhen, D, Lemckert, A, van Ooij, M (2013). Better cells for better health. *BMC Proc* 7 (suppl. 6): P1–P11.

23. Vellinga, J, Smith, JP, Lipiec, A, Majhen, D, Lemckert, A, van Ooij, M (2013). 23rd European Society for Animal Cell Technology (ESACT) meeting: better cells for better health. *BMC Proc* 7 (suppl. 6): P1–P11.

24. Cotmore, SF and Tattersall, P (2007). Parvoviral host range and cell entry mechanisms. *EMBO J* 17: 3351–3362.

25. Strong, JE, Coffey, MC, Tang, D, Sablin, P and Lee, PW (1998). Role of the receptor for measles and paramyxovirus in the attachment of virus to susceptible cells. *J. Virol* 72: 955–959.

26. Strong, JE, Coffey, MC, Tang, D, Sablin, P and Lee, PW (1998). Role of the receptor for measles and paramyxovirus in the attachment of virus to susceptible cells. *J. Virol* 72: 955–959.

27. Dörig, RE, Marcil, A, Chopra, A and Richardson, CD (1993). The human CD46 molecule is a neutral receptor for measles virus. *Hum Gene Ther* 4: 560–571.

28. Roizman, B (1979). The structure and isomerization of herpes simplex virus genomes. *Rev. Infect. Dis.* 1: 1045–1056.

29. Roizman, B (1979). The structure and isomerization of herpes simplex virus genomes. *Rev. Infect. Dis.* 1: 1045–1056.

30. Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RS, Scott, KJ, Coffey, M and Markert, J (2009). The molecular basis for the efficient infection of tumour cells by oncolytic adenovirus vectors. *Cancer Res* 69: 4919–4926.

31. Shabram, PW, Giroux, DD, Goudreau, AM, Gregory, LC and Federspiel, MJ (2011). Manufacture of measles virus particles? *Virology* 411: 108–118.

32. Chakrabarty, R, Tran, H, Gregori, D, Mercier, T, Senzer, N, Cheseby, J et al. (2015). Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. *Sci Transl Med* 5: 185ra63.

33. Heo, J, Breitbach, CJ, Moon, A, Heo, J, Lee, YK, Cho, M et al. (2015). Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. *Sci Transl Med* 5: 185ra63.

34. Langfield, KK, Walker, HJ, Gregory, LC and Federspiel, MJ (2011). Manufacture of measles virus. *Methods Mol Biol* 737: 345–366.

35. Strong, JE, Coffey, MC, Tang, D, Sablin, P and Lee, PW (1998). Role of the receptor for measles and paramyxovirus in the attachment of virus to susceptible cells. *J. Virol* 72: 955–959.

36. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

37. Strong, JE, Coffey, MC, Tang, D, Sablin, P and Lee, PW (1998). Role of the receptor for measles and paramyxovirus in the attachment of virus to susceptible cells. *J. Virol* 72: 955–959.

38. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

39. Strong, JE, Coffey, MC, Tang, D, Sablin, P and Lee, PW (1998). Role of the receptor for measles and paramyxovirus in the attachment of virus to susceptible cells. *J. Virol* 72: 955–959.

40. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

41. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

42. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

43. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

44. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

45. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

46. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

47. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

48. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

49. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

50. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

51. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

52. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

53. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

54. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

55. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

56. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

57. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

58. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

59. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

60. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.

61. Cotmore, SF and Tattersall, P (2007). Parvovirus host range and cell entry mechanisms. *Adv Virus Res* 70: 183–232.
69. Galanis, E, Atherton, PJ, Maurer, MJ, Knutson, KL, Dowdy, SC, Cliby, WA et al. (2015). Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. *Cancer Res* **75**: 22–30.

70. Galanis, E, Hartmann, LC, Cliby, WA, Long, HJ, Peethambaram, PP, Barrett, BA et al. (2010). Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. *Cancer Res* **70**: 875–882.

71. Geletneky, K, Huesing, J, Rommelaere, J, Schlehofer, JR, Leuchs, B, Dahm, M et al. (2012). Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. *BMC Cancer* **12**: 99.

72. Angelova, AL, Geletneky, K, Nüesch, JP and Rommelaere, J (2015). Tumor selectivity of oncolytic parvoviruses: from *in vitro* and animal models to cancer patients. *Front Bioeng Biotechnol* **3**: 55.

73. Geletneky, K, Nüesch, JP, Angelova, A, Kiprianova, I and Rommelaere, J (2015). Double-faceted mechanism of parvoviral oncosuppression. *Curr Opin Virol* **13**: 17–24.

74. Lang, FF, Bruner, JM, Fuller, GN, Aldape, K, Prados, MD, Chang, S et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. *J Clin Oncol* **21**: 2508–2518.

75. Tolcher, AW, Hao, D, de Bono, J, Miller, A, Patnaik, A, Hammond, LA et al. (2006). Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. *J Clin Oncol* **24**: 2052–2058.